Clearmind Medicine

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of a U.S. patent application for its non-hallucinogenic compound, MEAI, aimed at treating cocaine addiction. This patent strengthens Clearminds intellectual property portfolio and highlights MEAIs potential to address the unmet medical need for cocaine use disorder, which currently lacks FDA-approved treatments. The global market for cocaine addiction treatment is projected to grow significantly, underscoring the demand for new solutions. MEAI is designed to modulate serotonin and dopamine pathways, offering a safer alternative to existing interventions. Clearmind aims to position itself as a leader in next-generation addiction therapeutics.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has reached a significant milestone in its Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate targeting Alcohol Use Disorder (AUD). The trial, approved by the FDA, has successfully enrolled and treated six patients across prestigious institutions like Johns Hopkins University and Yale School of Medicine. This development marks a pivotal step in advancing CMND-100 as a potential innovative therapy for AUD, a condition with a substantial unmet need. The global alcohol-dependency treatment market is projected to reach $20 billion by 2032, highlighting the commercial opportunity for new therapeutic approaches. Clearminds commitment to delivering psychedelic-derived solutions aims to transform the treatment landscape for AUD.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, is focused on developing novel psychedelic-derived therapeutics to address major under-treated health issues such as alcohol use disorder, cocaine addiction, and obesity. The companys CEO, Dr. Adi Zuloff-Shani, will be a featured speaker at the Women in Psychedelic Leadership: Driving Innovation & Governance webinar hosted by the Psychedelic Association of Canada. This event highlights Clearminds commitment to advancing psychedelic medicine through scientific innovation and ethical leadership. The company holds a significant intellectual portfolio and is listed on Nasdaq and the Frankfurt Stock Exchange.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has appointed Mary-Elizabeth Gifford as Chief of Global Impact. Gifford will focus on strengthening Clearminds US partnerships and regulatory advocacy, particularly in Washington, D.C. and New York. Clearmind is engaged in clinical trials at prestigious institutions like Yale and Johns Hopkins, aiming to advance psychedelic therapeutics. Giffords expertise in psychedelic policies and her connections with government officials and investors are expected to bolster Clearminds position in the industry. The company holds a strong IP portfolio with 31 granted patents and is recognized for its scientific rigor.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the enrollment of the last patient for the first cohort of its Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived drug for Alcohol Use Disorder (AUD). The trial, conducted at Johns Hopkins University and Yale School of Medicine, aims to assess the safety and efficacy of CMND-100. The enrollment marks a significant milestone, with the company planning to expand the trial to additional sites in Israel. This progress highlights the growing interest in MEAI-based therapeutics and Clearminds commitment to addressing AUD, a condition with limited effective treatments.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the successful convening of its first Annual Scientific Advisory Board (SAB) meeting. The meeting focused on Clearminds lead candidate, MEAI, which is in Phase 1/2a clinical trials for Alcohol Use Disorder (AUD). The SAB, consisting of experts in psychiatry and metabolic disorders, provided strategic guidance on Clearminds clinical and preclinical programs. Discussions highlighted MEAIs potential as a safe and cost-effective treatment for AUD, obesity, and metabolic syndrome. The SAB also explored potential partnerships and reviewed Clearminds intellectual property portfolio, which includes 31 granted patents. The insights from the SAB are expected to guide Clearminds development strategy in advancing psychedelic-derived therapies.

growth-positive

Clearmind Medicine (CMND) announced on Friday that it has signed a securities purchase agreement with institutional investors. This development is expected to have a positive impact on the companys growth, as it involves an investment that could provide additional resources for Clearmind Medicine to expand its operations or further its research and development efforts. The details of the investment amount or the specific terms of the agreement were not disclosed in the article. The announcement was made on September 19, 2025.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced securities purchase agreements with institutional investors to issue convertible promissory notes up to $10 million. The initial notes were issued for $555,556 at a purchase price of $500,000. Aegis Capital Corp. acted as the financial advisor. The company plans to use the proceeds for working capital, corporate purposes, and potential acquisitions. Additional notes may be issued based on trading volume and other conditions. The notes have a 4% annual interest rate, increasing to 14% upon default, and are repayable in ten monthly installments starting 18 months after issuance.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of an international patent application under the Patent Cooperation Treaty. This is part of its collaboration with SciSparc Ltd., focusing on developing novel psychedelic-derived therapeutics. The patent covers a combination therapy using Clearminds MEAI and SciSparcs PEA for treating metabolic syndrome and obesity. This marks a significant milestone in their collaboration, which has resulted in 13 patent families across multiple jurisdictions. The therapy aims to leverage MEAIs pharmacological profile and PEAs properties to offer a safe and effective treatment for metabolic conditions. Clearminds strategy is to develop breakthrough therapies for complex health conditions, potentially redefining therapeutic approaches for metabolic syndrome and obesity.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a significant milestone in its collaboration with Clearmind Medicine Inc. The partnership has resulted in the publication of an international patent application under the Patent Cooperation Treaty. This patent covers a novel combination therapy for treating metabolic syndrome and obesity, leveraging Clearminds MEAI and SciSparcs PEA. The collaboration aims to develop innovative therapies for mental health disorders and metabolic conditions. SciSparc focuses on cannabinoid pharmaceuticals and is engaged in drug development programs for conditions like Tourette Syndrome and Alzheimers disease. The company also has a subsidiary selling hemp seed oil products on Amazon.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has received Institutional Review Board (IRB) approval from Hadassah Medical Center in Jerusalem for its Phase 1/2a clinical trial of CMND-100, a psychedelic-derived oral drug candidate for Alcohol Use Disorder (AUD). This approval follows FDA clearance and other IRB approvals, allowing patient enrollment at Hadassah. The trial, involving institutions like Yale and Johns Hopkins, aims to assess the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings and consumption. The study represents a significant step in addressing AUD, a major global health issue, and highlights Clearminds commitment to pioneering next-generation therapies.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a new international patent application in collaboration with Clearmind Medicine Inc. This patent covers a combination therapy designed to address obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The therapy leverages the pharmacological profile of MEAI and the properties of PEA. This development is part of an ongoing collaboration between SciSparc and Clearmind, which has already resulted in multiple patent applications. SciSparc focuses on developing cannabinoid-based pharmaceuticals and has several drug development programs targeting disorders like Tourette Syndrome and Alzheimers disease.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the filing of a new international patent application under the Patent Cooperation Treaty. The patent covers a novel combination therapy using MEAI and Palmitoylethanolamide (PEA) to address obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). These conditions affect a significant portion of the global population, with limited treatment options currently available. Clearminds approach leverages the pharmacological profile of MEAI and the anti-inflammatory properties of PEA. This development is part of Clearminds collaboration with SciSparc Ltd., aiming to provide innovative solutions for unmet medical needs. The company holds a robust intellectual property portfolio and continues to seek additional patents.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the successful initiation of a Phase I/IIa clinical trial at Tel Aviv Sourasky Medical Center for its drug candidate CMND-100, aimed at treating Alcohol Use Disorder (AUD). The trial, also conducted at Yale, Johns Hopkins, and Hadassah, assesses the safety and efficacy of CMND-100, which uses the molecule 5-methoxy-2-aminoindane (MEAI) to reduce alcohol cravings. This milestone strengthens Clearminds clinical network and accelerates patient enrollment, marking a significant step towards offering an innovative treatment for AUD. The collaboration with leading medical centers underscores the scientific communitys confidence in Clearminds approach.

growth-positive

Aurora Cannabis, a leading Canadian medical cannabis company, has received EU-GMP certification for its distribution facility in Brampton, Ontario. This certification marks a significant milestone in Auroras international expansion, particularly in Europe, where the demand for regulated cannabis products is increasing. The Brampton facility is now Auroras fourth EU-GMP-certified site, enhancing its ability to provide high-quality medical cannabis globally. The certification is a testament to Auroras commitment to maintaining stringent quality standards, positioning it as a major player in the international medical cannabis market.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the expansion of its Phase I/IIa clinical trial for CMND-100, a MEAI-based treatment for Alcohol Use Disorder (AUD). The trial, which evaluates the safety and efficacy of CMND-100, has added a new site at Johns Hopkins University School of Medicine and enrolled its first participant there. This expansion follows the initial enrollment at Yale School of Medicine, highlighting the growing interest in CMND-100 as a potential treatment for AUD. Clearmind aims to redefine the treatment landscape for AUD through this multinational, multicenter study, which could lead to further development of the therapy.

growth-positive

The global alcohol use disorder market is experiencing significant growth due to the demand for innovative and personalized treatments, and the integration of digital health technologies. Companies like Adial Pharmaceuticals and Clearmind Medicine are at the forefront of these advancements. The market is expected to expand robustly from 2025 to 2035, driven by personalized medicine, new pharmacotherapies, and digital health technologies like telemedicine. Despite challenges such as high costs and stigma, the market shows potential for further growth. Strategic collaborations and partnerships are key to tapping into untapped revenue opportunities.

The article provides a brief update on the performance of healthcare stocks on a Thursday afternoon, noting that the NYSE Health Care Index was down by 0.1%. However, the article is behind a paywall, and further details are not accessible without a subscription to MT Newswires. The article mentions several stock symbols, including AZN.L, SMMT, XLV, TH.TO, and CMND, but does not provide specific information about any particular company or event. As such, no detailed analysis or classification of impact, issues, or other specifics can be determined from the available text.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center for its Phase 1/2a clinical trial of CMND-100, a novel psychedelic-derived drug for treating Alcohol Use Disorder (AUD). This approval allows patient enrollment at the site, marking a significant step in the trial, which also involves Yale School of Medicine, Johns Hopkins University, and Hadassah-University Medical Center. The trial aims to evaluate the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings and consumption. Clearmind has previously received FDA clearance for its Investigational New Drug application, and this milestone is expected to advance the development of transformative treatments for AUD.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has dosed its first participant with CMND-100, a novel psychedelic-derived therapeutic, in a Phase I/IIa clinical trial aimed at treating Alcohol Use Disorder (AUD). This marks a significant milestone for the company as it is the first time their proprietary compound has been administered in a clinical setting. The trial, conducted at prestigious institutions like Yale and Johns Hopkins, aims to evaluate the safety, tolerability, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption. This development represents a potential breakthrough for millions affected by AUD worldwide.

growth-positive

Compass Pathways announced the achievement of the primary endpoint in their Phase 3 COMP005 trial for COMP360, a synthetic psilocybin formulation for treatment-resistant depression. The trial showed a statistically significant reduction in symptom severity compared to placebo. The company plans to discuss these findings with the FDA, although the data has not yet been reviewed. The trial involved 258 participants across 32 sites in the U.S. and demonstrated consistent safety findings with no new safety concerns. The CEO highlighted the innovative potential of psilocybin in mental health care. Despite positive results, Evercore ISI downgraded Compass Pathways due to concerns about the durability of the treatments effects.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the addition of Hadassah-University Medical Center in Jerusalem as a new clinical site for its ongoing Phase I/IIa trial of CMND-100, a psychedelic-derived drug for Alcohol Use Disorder (AUD). This expansion includes prestigious institutions like Yale and Johns Hopkins, enhancing patient recruitment and data collection. The trial aims to evaluate the safety and efficacy of CMND-100 in reducing alcohol cravings. With AUD affecting over 280 million people globally, the trial represents a significant market opportunity. Clearminds CEO, Dr. Adi Zuloff-Shani, emphasized the importance of this addition in validating CMND-100s potential and advancing their mission to offer novel therapeutic solutions.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has enrolled its first patient in a Phase I/IIa clinical trial for CMND-100, a novel MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD). The trial, conducted at Yale School of Medicine, marks a significant milestone in evaluating the safety and efficacy of CMND-100. The study targets individuals aged 18 to 60 who are either heavy binge drinkers or diagnosed with AUD. Clearminds CEO, Dr. Adi Zuloff-Shani, highlighted the potential of this innovative treatment to address unmet medical needs in the AUD market, which is projected to grow significantly. The companys efforts are part of a broader strategy to develop effective psychedelic-derived therapeutics.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has partnered with a prominent government and political affairs consulting firm to advance its mission of integrating psychedelic-based treatments into mainstream healthcare. This partnership aims to navigate the complex regulatory landscape and foster acceptance among U.S. policymakers for psychedelic therapies, which have shown potential in treating mental health disorders like PTSD. The collaboration will focus on educating policymakers, developing balanced regulations, and forming strategic alliances to support Clearminds innovative pipeline, including its lead candidate, CMND-100, currently in Phase I/IIa clinical trials for alcohol use disorder at Yale School of Medicine and Johns Hopkins University.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the expansion of its Phase I/IIa clinical trial for CMND-100, a psychedelic-derived drug candidate for Alcohol Use Disorder (AUD). The trial now includes Tel Aviv Sourasky Medical Center, joining Yale School of Medicine and Johns Hopkins University. This expansion follows the enrollment of the first patient and aims to enhance the trials capacity to evaluate the drugs safety and efficacy. Clearmind focuses on developing novel psychedelic-derived therapeutics and holds a robust intellectual property portfolio. The companys efforts are directed towards addressing the global burden of AUD, which affects millions worldwide.

growth-positive

The article discusses several key developments involving U.S. President Donald Trump. Notably, Trump plans to sign an executive order to delay enforcement of a law that could ban or force the sale of TikTok, allowing the platform to continue operating in the U.S. for another 90 days. This move is seen as growth-positive for TikTok as it provides more time to ensure data security and compliance. Additionally, the U.S. Senate has passed a bill to establish a regulatory framework for stablecoins, and there is growing support within the Trump administration for the use of psychedelics in mental health treatment. These developments could impact various publicly traded companies in the tech, cryptocurrency, and psychedelic sectors.

growth-positive

The article discusses the potential growth in the psychedelic field, highlighting favorable sentiments from key U.S. officials, including Robert F. Kennedy Jr. and Casey Means, towards psychedelics as mental health treatments. Publicly traded companies like Atai Life Sciences are expected to benefit from this positive outlook. Atai Life Sciences is merging with Beckley Psytech in an all-share transaction, which is seen as a strategic move to strengthen their pipeline. The article suggests that the merger and supportive policy environment could lead to growth opportunities for companies in the psychedelic space.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has partnered with a leading government and political affairs firm to advance its psychedelic-derived therapeutics. This collaboration aims to navigate regulatory landscapes and foster acceptance among U.S. policymakers for psychedelic treatments, particularly for conditions like PTSD. The partnership will help Clearmind advocate for science-based regulatory frameworks and strategic alliances to support its innovative pipeline, including its lead candidate, CMND-100, currently in Phase I/IIa clinical trials. Clearminds focus is on developing and commercializing psychedelic-based compounds to address under-treated health issues.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the enrollment of the first patient in its Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived therapeutic aimed at treating Alcohol Use Disorder (AUD). The trial, conducted at Yale School of Medicine, marks a significant milestone in evaluating the safety, tolerability, and efficacy of CMND-100. This development is a pivotal step towards offering a groundbreaking treatment for AUD, addressing a major unmet medical need. The substance use disorder treatment market is projected to grow significantly, highlighting the potential impact of Clearminds innovative therapy.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, is hosting a live webinar titled Gazing Through the Crystal Ball on May 21, 2025. The event will feature a panel of experts discussing the evolving landscape of psychedelic science and business, particularly in the context of changing FDA policies and political climates. The company is focused on developing novel psychedelic-derived therapeutics, with its treatment for Alcohol Use Disorder, CMND-100, recently advancing into FDA-approved clinical trials. The webinar will include notable speakers such as Rick Doblin, Robin Carhart-Harris, and Clearminds CEO, Dr. Adi Zuloff-Shani.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of a European patent application for its proprietary psychedelic-based combination therapy aimed at treating cocaine addiction. This patent strengthens Clearminds global intellectual property portfolio and supports its strategic focus on addiction treatment. The therapy, which includes MEAI and certain N-Acylethanolamines, has shown promising preclinical results in reducing cocaine cravings without affecting natural reward responses. The patent is part of Clearminds collaboration with SciSparc Ltd. to explore the potential of MEAI and PEA-based technologies for treating central nervous system disorders. This development marks a significant milestone in Clearminds mission to develop effective, non-addictive therapies for substance use disorders.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a collaboration with Clearmind Medicine Inc. to file a new international patent application for a treatment targeting eating disorders such as anorexia and bulimia. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparcs Palmitoylethanolamide (PEA) to address the neurobiological and psychological factors of these disorders. This collaboration represents a strategic move to expand SciSparcs portfolio in cannabinoid pharmaceuticals and psychedelic-derived therapeutics. The partnership with Clearmind Medicine, a clinical-stage psychedelic pharmaceutical company, aims to leverage both companies expertise in developing innovative treatments for mental health conditions.

growth-positive

Clearmind Medicine has initiated its U.S. clinical trial site at Yale School of Medicine for its Phase I/IIa trial in Alcohol Use Disorder (AUD). The company has completed all necessary preparations, including obtaining FDA approval and setting up partnerships with Yale and Johns Hopkins University. The trial will assess the efficacy of CMND-100, a drug candidate aimed at transforming the treatment landscape for alcoholism. Meanwhile, Compass Pathways has completed dosing for Part A of its Phase 3 trial for treatment-resistant depression, with results expected in June. Both companies are advancing their research in psychedelics, aiming to address significant public health challenges.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the filing of a new international patent application for a treatment targeting eating disorders such as anorexia and bulimia. The treatment involves a combination of 3-Methylmethcathinone (3-MMC) and Palmitoylethanolamide (PEA), aiming to address the neurobiological and psychological factors associated with these conditions. Eating disorders are significant mental health issues with a high prevalence and mortality rate. Clearmind focuses on developing psychedelic-derived therapeutics to tackle under-treated mental health problems. The company is committed to advancing its pipeline through scientific research and clinical trials, with a portfolio of 19 patent families and 31 granted patents.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has initiated its U.S. clinical trial site at Yale School of Medicine for its Phase I/IIa clinical trial targeting Alcohol Use Disorder (AUD). The company has received FDA approval for its Investigational New Drug (IND) application and has activated all planned sites for the trial, including Johns Hopkins University and the IMCA Center in Israel. The trial will be led by Dr. Anahita Bassir Nia, focusing on the treatment of alcoholism using Clearminds drug candidate, CMND-100. This marks a significant step in addressing the urgent public health challenge of AUD.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company based in Vancouver, is hosting a live webinar titled Gazing Through the Crystal Ball on May 21, 2025. The event will feature a panel of experts discussing the evolving landscape of psychedelic science and business, particularly in the context of changing FDA policies and political climates. The company is focused on developing novel psychedelic-derived therapeutics, with its treatment for Alcohol Use Disorder, CMND-100, recently advancing into FDA-approved clinical trials. The webinar aims to enhance public engagement and awareness in the psychedelic space.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced that the United States Patent Office has issued a Notice of Allowance for a patent related to its MEAI treatment for binge behavior. This development strengthens Clearminds intellectual property portfolio and supports its position in the psychedelic-derived therapeutics space. The company focuses on discovering and developing novel treatments for under-treated health issues, such as alcohol use disorder. Clearminds portfolio includes 19 patent families with 31 granted patents, and it plans to continue expanding its intellectual property. The companys shares are traded on Nasdaq and the Frankfurt Stock Exchange.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has initiated a Phase I/IIa clinical trial for its novel psychedelic-derived therapeutic, CMND-100, targeting Alcohol Use Disorder (AUD). The trial, conducted at Johns Hopkins University School of Medicine, Yale School of Medicine, and IMCA Center in Israel, aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100. This marks a significant milestone in Clearminds mission to provide innovative solutions for addictions and mental health disorders. The study will also assess the drugs potential efficacy in reducing alcohol cravings and consumption. The involvement of prestigious institutions underscores the potential of CMND-100 as a breakthrough treatment, paving the way for FDA approval.

growth-positive

Clearmind Medicine has initiated its Phase I/IIa clinical trial for CMND-100 at Johns Hopkins University School of Medicine, marking a significant milestone in its mission to develop treatments for alcohol use disorder and other mental health conditions. The trial aims to investigate the safety and pharmacokinetic profile of CMND-100. This development is part of Clearminds broader strategy to gain FDA approval for its psychedelic-based therapeutic platform. Additionally, the company has filed an international patent application in collaboration with Yissum Research Development Company. Filament Health also reported FDA authorization for a Phase 2 trial of its drug candidate PEX010 for opioid use disorder, funded by Wellcome Leap.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has initiated a Phase I/IIa clinical trial for its novel psychedelic-derived therapeutic, CMND-100, targeting Alcohol Use Disorder (AUD). The trial, which marks the first clinical application of the CMND-100 platform, is being conducted at prestigious institutions including Johns Hopkins University and Yale School of Medicine. The study aims to assess the safety, tolerability, and pharmacokinetics of CMND-100, with preliminary evaluations of its efficacy in reducing alcohol cravings and consumption. This milestone is a significant step towards FDA approval and reflects the potential of CMND-100 as a breakthrough treatment for AUD.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of an international patent application in collaboration with Yissum Research Development Company. The patent covers innovative psychedelic-based compounds for treating mental health disorders and addiction. This collaboration aims to transform mental health treatment through next-generation psychedelic-based therapeutics. The patent is part of Clearmind’s exclusive worldwide licensing agreement with Yissum, enhancing their portfolio in addiction and mental health treatments. Clearmind is focused on developing novel psychedelic-derived therapeutics to address under-treated health problems, including alcohol use disorder. The company holds a significant intellectual property portfolio and plans to expand it further.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has launched its Electronic Data Capture (EDC) system to support its Phase I/II clinical trial for a MEAI-based treatment targeting Alcohol Use Disorder (AUD). This system is designed to enhance data collection, monitoring, and compliance across all study stages. The EDC platform, custom-designed for Clearminds clinical protocol, incorporates features like automated edit checks and real-time validation, ensuring accurate tracking of safety events and patient allocation. This operational milestone is crucial for advancing Clearminds psychedelic-derived therapeutics through clinical development.

growth-positive

Clearmind Medicine, a psychedelic pharmaceutical biotech company, is focused on developing therapeutics for underserved health issues, particularly in addiction treatment. The company is in the clinical stage, working on a proprietary molecule called MEAI for treating addiction. MEAI is a non-hallucinogenic psychoactive compound that has shown promise in pre-clinical trials for reducing alcohol consumption with a euphoric effect. The company aims to offer a cost-effective alternative to traditional addiction treatments and psychedelic therapies by eliminating the need for therapy sessions and facilities. Clearmind Medicine is well-positioned to compete in the addiction treatment market.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the arrival of its drug candidate, CMND-100, in the U.S. for an FDA-approved Phase I/IIa clinical trial targeting Alcohol Use Disorder (AUD). This milestone marks a significant step towards demonstrating the drugs potential as a transformative treatment for AUD, a condition affecting over 28 million adults in the U.S. The trial will assess the safety and efficacy of CMND-100, which is based on a novel mechanism of action to reduce alcohol consumption and cravings. The study will be conducted at Yale School of Medicine and Johns Hopkins University, with an additional trial in Israel. Clearmind aims to disrupt the $35 billion global AUD treatment market with its innovative therapeutic.

growth-negative

The article discusses recent developments in psychedelic stocks, focusing on atai Life Sciences and NRx Pharmaceuticals. atai Life Sciences reported a fourth-quarter loss, with cash reserves significantly reduced compared to the previous year. However, a recent equity offering raised $59.2M, extending their financial runway into 2027. The company is focused on advancing its Phase 2 clinical trials for VLS-01 and EMP-01, with results expected in 2026. NRx Pharmaceuticals also reported a loss but highlighted strategic advancements, including a New Drug Application for NRX-100 and progress towards accelerated approval for NRX-101. Both companies are making strides in mental health treatments, despite financial challenges.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has signed a non-binding Letter of Intent with Polyrizon Ltd. to develop a novel intranasal formulation for its psychedelic-based treatments. The collaboration aims to enhance the bioavailability and therapeutic effect of Clearminds drug candidate, 5-Methoxy-2-aminoindane (MEAI), potentially in combination with Palmitoylethanolamide (PEA). The initiative will explore the feasibility of intranasal drug delivery, which could offer advantages such as faster absorption and increased patient compliance. Clearmind will fund the research and development process, while Polyrizon will advance formulation development. If successful, a definitive agreement will be negotiated.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has initiated its Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived therapeutic aimed at treating Alcohol Use Disorder (AUD). This marks the first clinical application of their proprietary drug platform. The trial will assess the safety, tolerability, and pharmacokinetics of CMND-100, with preliminary evaluations on its efficacy in reducing alcohol cravings. The study is being conducted at IMCA in Israel and two U.S. institutions: Yale School of Medicine and Johns Hopkins University. This development is a significant milestone for Clearmind, as it transitions to a clinical-stage company, addressing the global challenge of AUD with innovative solutions.

growth-positive

The article discusses recent developments in the psychedelic stock market, focusing on atai Life Sciences and MIRA Pharmaceuticals. atai Life Sciences has dosed its first patient in the Phase 2 Elumina trial for VLS-01, a treatment for treatment-resistant depression. This marks a significant milestone in their efforts to transform mental health treatment. The trial aims to assess the efficacy, safety, and tolerability of VLS-01, with results expected in Q1 2026. Meanwhile, MIRA Pharmaceuticals is expanding its Ketamir-2 development by formulating it into a topical treatment for localized pain, enhancing their pain management portfolio.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a significant development in its collaboration with Clearmind Medicine Inc. The partnership has resulted in a patent application published by the South Korean Intellectual Property Office for a combination treatment targeting cocaine addiction. The treatment combines Clearminds MEAI and SciSparcs PEA, showing promising preclinical trial results. The study demonstrated that MEAI effectively reduces cocaine-seeking behavior without affecting natural reward responses. This collaboration adds to multiple patent applications filed globally, enhancing SciSparcs portfolio in cannabinoid pharmaceuticals. SciSparc is actively developing therapies for various disorders, including Tourette Syndrome and Alzheimers disease.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of a patent by the Korean Intellectual Property Office for its combination therapy of MEAI and N-Acylethanolamines aimed at treating cocaine addiction. The patent is based on preclinical trials showing MEAIs effectiveness in reducing cocaine cravings without affecting natural reward responses. This development is part of Clearminds collaboration with SciSparc Ltd., focusing on combining Clearminds psychedelic treatment with SciSparcs PEA. Clearmind is committed to expanding its intellectual property portfolio, which currently includes 19 patent families and 31 granted patents, as it continues to develop psychedelic-derived therapeutics for under-treated health issues.

growth-negative

GH Research reported a FY24 loss per share of (75c), slightly better than analyst estimates. The company has $182.6M in cash and equivalents as of December 31, 2023. Their Investigational New Drug Application for GH001 is on clinical hold by the FDA, which requested additional inhalation toxicology studies and device design verification. GH Research has completed the necessary studies and is preparing to respond to the FDA by mid-2025. Compass Pathways also reported a loss and expects its cash position to fund operations through the second half of 2026.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a collaboration with Clearmind Medicine Inc. to develop innovative combination therapies using psychedelic molecules and N-Acylethanolamines. The partnership has led to a patent application in Mexico for a combination therapy addressing binge behavior. SciSparc focuses on cannabinoid pharmaceuticals and is engaged in drug development programs for conditions like Tourette Syndrome and Alzheimers disease. The collaboration with Clearmind, a biotech company specializing in psychedelic-derived therapeutics, has resulted in 13 patents filed in the U.S. and other jurisdictions. This partnership aims to address under-treated mental health issues through novel therapeutic approaches.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of a patent by the Instituto Mexicano de la Propriedad Industrial. The patent covers an innovative combination therapy of MEAI and N-Acylethanolamines, aimed at addressing binge behaviors such as alcohol consumption and eating. This development is part of Clearminds collaboration with SciSparc Ltd., a clinical-stage pharmaceutical company. Clearmind focuses on developing psychedelic-derived therapeutics for under-treated health issues, with a portfolio of 19 patent families and 31 granted patents. The company is listed on Nasdaq and the Frankfurt Stock Exchange. This patent publication is a positive step in Clearminds mission to commercialize psychedelic-based compounds as regulated medicines.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company focused on psychedelic-derived therapeutics, announced that all resolutions proposed at its shareholder meeting on January 6, 2025, were approved. These include fixing the board of directors at five members, electing directors for the upcoming year, appointing Brightman Almagor Zohar & Co. as auditors, and establishing an omnibus equity incentive plan. Additionally, a resolution was passed to allow for a potential consolidation of shares. Clearmind is focused on developing treatments for under-treated health issues, such as alcohol use disorder, and holds a robust intellectual property portfolio. The company is listed on Nasdaq and the Frankfurt Stock Exchange.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of a European patent application for its innovative combination therapy involving MEAI and N-Acylethanolamines. This therapy targets binge behaviors such as alcohol consumption and eating. The patent application is part of Clearminds collaboration with SciSparc Ltd., a specialty pharmaceutical company. Clearmind has filed 13 patents in the US and other jurisdictions related to this collaboration. The company aims to establish itself as a leader in psychedelic-derived therapeutics by building a robust intellectual property portfolio. Clearminds shares are traded on Nasdaq and the Frankfurt Stock Exchange.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a collaboration with Clearmind Medicine Inc. to develop innovative combination therapies using psychedelic molecules and N-acylethanolamines. This partnership has led to the filing of a European patent application by Clearmind for a therapy targeting binge behaviors. SciSparc focuses on cannabinoid pharmaceuticals and is engaged in drug development programs for conditions like Tourette Syndrome and Alzheimers disease. Clearmind, a clinical-stage psychedelic biotech company, aims to develop and commercialize psychedelic-based therapeutics. The collaboration has resulted in thirteen patents filed in the US and other jurisdictions, indicating a growth-positive impact for SciSparc.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has announced the approval of a new patent by the Macau International Intellectual Property Office. This patent is part of Clearminds MEAI-based binge behavior regulator program, which focuses on developing novel psychedelic-derived therapeutics to address major under-treated health problems, such as substance addictions. The patent approval in Macau strengthens Clearminds global intellectual property portfolio, which now includes 31 granted patents across 18 patent families. The company aims to establish a proprietary and differentiated IP portfolio in the psychedelic space, focusing on non-hallucinogenic molecules. Clearminds mission is to develop transformative treatments that address the underlying mechanisms of binge behaviors, helping individuals regain control over their lives.

growth-positive

Clearmind Medicine has signed a non-binding term sheet with Dr. Glitter Pty Ltd to collaborate on the development and commercialization of a MEAI-based alcohol substitute using Dr. Glitters ActivCrystal technology. This partnership aims to create an alcohol alternative that replicates the sensations of drinking without health risks. The collaboration marks a significant step in Clearminds strategy to introduce innovative solutions for alcohol misuse to global markets. The term sheet outlines preliminary terms that will be finalized in a definitive agreement, setting a framework for advancing their innovations.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has signed a non-binding term sheet with Dr. Glitter Pty Ltd to collaborate on the development and commercialization of Clearmind’s MEAI-based alcohol substitute using Dr. Glitters ActivCrystal™ technology. This partnership aims to create an innovative alcohol alternative that can be sprinkled on food or beverages, offering the sensations of alcohol without its health risks. The collaboration represents a significant step in Clearminds strategy to address alcohol misuse globally. The partnership is expected to advance Clearminds product development and market reach, potentially transforming social drinking by providing a safer alternative.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be conducted at Yale School of Medicine’s Department of Psychiatry, led by Dr. Anahita Bassir Nia. This approval marks a significant milestone in Clearminds FDA-regulated clinical program, expanding the multi-site trial to evaluate the safety, tolerability, and efficacy of CMND-100. The trial aims to address the critical gap in effective treatments for AUD, a condition responsible for millions of deaths annually. Clearminds proprietary drug, CMND-100, is designed to reduce alcohol cravings and consumption, offering a potential solution to this widespread health issue.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health technology company. The collaboration focuses on developing and commercializing Clearminds MEAI-based alcohol substitute using Dr. Glitters ActivCrystal™ technology. This partnership aims to create an alcohol alternative that replicates the sensations of drinking without the health risks. The collaboration is expected to advance Clearminds strategy to introduce MEAI to global markets, addressing alcohol misuse. This partnership marks a significant step in Clearminds mission to transform social drinking by offering a safe alternative to alcohol.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced it has received Institutional Review Board (IRB) approval for part A of its Phase I/IIa clinical trial in the U.S. for treating alcohol use disorder (AUD). This approval follows the FDAs approval of their Investigational New Drug (IND) application. The trial will assess the safety and pharmacokinetics of Clearminds MEAI-based treatment, CMND-100, at multiple sites, including Johns Hopkins University and Yale School of Medicine. The company aims to offer new hope for those suffering from alcohol addiction, a major global health issue. Clearminds portfolio includes 29 granted patents, and it plans to expand its intellectual property. The companys shares are listed on Nasdaq and the Frankfurt Stock Exchange.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of an international patent application for its combination therapy of Ibogaine and N-Acylethanolamines. This development is part of a collaboration with SciSparc Ltd., focusing on enhancing the safety and efficacy of treatments for mental health and addiction. The patent aims to solidify Clearminds leadership in the psychedelics space by building a diverse portfolio of technologies. The company is committed to providing safe and effective solutions for mental health conditions with unmet needs.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the submission of a patent application under the International Patent Cooperation Treaty. This is part of their ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent covers innovative compounds designed to treat PTSD and other mental health conditions. The global market for PTSD treatment is expected to grow significantly, highlighting the importance of Clearminds developments. The company aims to provide effective and safe treatments for PTSD, addressing the limitations of current pharmacological options.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of an international patent application for a novel combination of MDMA and N-Acylethanolamines. This development is part of an ongoing collaboration with SciSparc Ltd. The combination aims to enhance the safety and efficacy of MDMA by reducing its dosage while maintaining therapeutic benefits. The company has filed thirteen patents related to this collaboration. This strategic move is expected to pave the way for new treatments in mental health and addiction. Clearminds CEO emphasized the companys commitment to innovative and effective treatments.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, announced the publication of an international patent application for a combination therapy involving MDMA and N-Acylethanolamines, developed in collaboration with Clearmind Medicine Inc. This collaboration aims to enhance the safety and efficacy of treatments for mental health and addiction disorders. Thirteen patents related to this collaboration have been filed. The announcement underscores the potential of this combined approach to address regulatory concerns and improve therapeutic outcomes.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of its patent application under the international Patent Cooperation Treaty for innovative combinations of Ketamine and N-Acylethanolamines. This patent application is a result of its collaboration with SciSparc Ltd., a pharmaceutical company specializing in treatments for central nervous system disorders. The collaboration focuses on researching combination therapies to treat addictions, promote weight loss, and address mental health disorders. To date, thirteen patents related to this collaboration have been filed. The announcement highlights the potential of these therapies to reduce treatment doses while maintaining effectiveness and minimizing side effects. Clearmind aims to provide safe and effective treatments with minimized adverse effects.

growth-negative

The Cannabist Co., a New York-based cannabis operator, announced the sale of its Florida assets, including 14 dispensaries and three cultivation facilities, for $16.4 million. This move is part of the companys strategy to reduce its operational footprint and eliminate loss-making operations. The sale is divided into two deals: one with an undisclosed MSO for $11.4 million and another with a joint venture between Mint Cannabis and Shango for $5 million. The Cannabist aims to focus on growth markets and optimize profitability, continuing to operate in 13 markets but planning to reduce to 12 states. The company has been selling off assets as part of its broader corporate restructuring efforts.

Growth-Positive

Clearmind Medicine Inc., a clinical-stage biotech company, has received a new patent approval from the United States Patent and Trademark Office. The patent is for a method of regulating the consumption of alcoholic beverages and controlling binge behavior through the administration of an amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the companys innovative psychedelic molecule. This latest patent further strengthens Clearmind’s extensive intellectual property portfolio in the psychedelic sector, which now includes 29 granted patents across 19 patent families, with protections secured in key jurisdictions such as the U.S., Europe, China, and India.

Growth-Positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has submitted a patent application for its third generation of psychedelic compounds. This is part of the companys ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent application pertains to the preparation and use of these compounds in the treatment of mental disorders. The submission will allow Clearmind to seek patent protection in major jurisdictions such as the US, Europe, China, and India. Clearminds CEO, Dr. Adi Zuloff-Shani, expressed confidence in the potential of psychedelic treatments in treating mental disorders.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, is collaborating with Clearmind Medicine to develop treatments for obesity and metabolic syndrome. The partnership combines SciSparc’s Palmitoylethanolamide (PEA) with Clearmind’s psychoactive molecule, MEAI. The collaboration has resulted in multiple patent applications for safer and more effective therapeutic options. A recent study showed that the treatment significantly reduced weight loss in diet-induced obesity in mice, improved glucose metabolism, increased energy expenditure and fat utilization, and decreased fatty liver. The treatment was well tolerated and led to increased oxygen consumption and carbon dioxide emission, indicating increases in the metabolic process and fat burn.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The study, led by Prof. Joseph Tam, revealed that MEAI significantly reduced diet-induced obesity in mice, improved metabolism, decreased fatty liver disease, and increased energy expenditure. The findings are based on Clearmind Medicine’s study aimed to investigate the ability of MEAI to modulate metabolism and counteract obesity. The companys CEO, Dr. Adi Zuloff-Shani, expressed excitement over the potential of MEAI in the treatment of obesity.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has successfully participated in the Psychedelic Medicine – Israel 2024 conference. The companys CEO, Adi Zuloff-Shani, presented a talk on the potential of 5-Methoxy-2-Aminoindane (MEAI) to regulate binge behaviors, particularly in treating addiction-related disorders. Researchers from The Hebrew University of Jerusalem also presented their findings on the promising results of MEAI in attenuating obesity and its related metabolic complications. The company aims to continue raising awareness of its innovative therapies among global organizations, establishing its presence, and creating a broad network of partners.

growth-positive

Clearmind Medicine Inc. has announced a strategic partnership with JS First Sdn. Bhd. The partnership aims to source global manufacturers and distributors for Clearminds MEAI-based alcohol substitute beverages. This follows Clearminds recent entry into the non-alcoholic beverage market with its proprietary, neurologically active novel alcohol replacement beverage, which was granted patents in the U.S., India, and Europe. JS First will conduct comprehensive research on manufacturing and licensing rights for Clearmind’s beverages in foreign markets, identify and secure manufacturing partners, and establish relationships with distributors across the globe.

Growth-Positive

Clearmind Medicine Inc., a clinical-stage biotech company, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for its proprietary MEAI-based CMND-100 oral capsule. This allows the company to proceed with a Phase I/IIa clinical trial in the United States for treating patients with alcohol use disorder (AUD). The company has also signed agreements to perform the clinical trial in leading universities in the United States, including Yale School of Medicine and Johns Hopkins University School of Medicine.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has submitted an additional patent application with the United States Patent and Trademark Office. This is part of its ongoing collaborations with SciSparc Ltd., a specialty clinical-stage pharmaceutical company, and Prof. Joseph Tam from the Hebrew University’s technology transfer company, Yissum. The patent application refers to the novel proprietary composition of Clearmind’s MEAI compound with Palmitoylethanolamide, the active ingredient of SciSparc’s proprietary CannAmide, for treating metabolic syndrome and obesity. The global obesity treatment market size was valued at $15 billion in 2022 and is expected to register a rapid revenue CAGR of 10.0% during the forecast period of 2023 to 2032.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has submitted an additional patent application with the United States Patent and Trademark Office. This is part of its ongoing collaboration with Clearmind Medicine Inc., a clinical-stage biotech company. The patent application is for a novel proprietary composition of Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide™ with Clearmind’s innovative MEAI compound for treating metabolic syndrome and obesity. The global obesity treatment market size was $15 billion in 2022 and is expected to grow at a compound annual growth rate of 10.0% during the forecast period.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announces its participation in the upcoming Psychedelic Medicine – Israel 2024 conference. The companys CEO, Adi Zullof-Shani, will present research on 5-Methoxy-2-Aminoindane (MEAI) as a potential regulator of binge behaviors and its application in treating addiction-related disorders. Additionally, researchers from The Hebrew University of Jerusalem will present their findings on MEAIs potential in attenuating obesity and its related metabolic complications.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has signed an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The agreement grants Clearmind exclusive global rights to further develop, manufacture, and commercialize compounds invented by Hebrew University professors for treating PTSD and other mental health conditions. The global market for PTSD treatment is expected to reach $27.37 billion by 2033. Clearmind is responsible for the ongoing development and potential commercialization in line with regulatory guidelines. The agreement includes future milestone payments, royalties on future sales, and commitments to safeguard intellectual property rights.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has announced progress in its proprietary MEAI-based alcohol substitute beverage program. The company has initiated the last pre-clinical study required for a novel-food application submission. Clearminds alcohol substitute has been granted patents in the U.S., India, and Europe. The project is led by Nicholas Kadysh, a former executive at Red Bull Canada and Juul Labs Canada. The no/low alcohol market is projected to grow at a volume CAGR of +6% between 2023 and 2027.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has announced progress in its proprietary MEAI-based alcohol substitute beverage program. The company has completed most of the pre-clinical studies required for a novel-food application submission. Clearmind’s alcohol substitute was granted patents in the U.S., India, and Europe. The project is led by former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh. The company believes that this progress is a signal to the market that they are on the verge of introducing a groundbreaking product that aligns with the growing global trend towards no- and low-alcohol consumption.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has signed an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The agreement grants Clearmind exclusive global rights to further develop, manufacture, and commercialize innovative compounds for treating PTSD and other mental health conditions. The global market for PTSD treatment is expected to reach $27.37 billion by 2033. Clearmind is responsible for the ongoing development and potential commercialization in line with regulatory guidelines. The agreement includes future milestone payments, royalties on future sales, and commitments to safeguard intellectual property rights.

Neutral

Clearmind Medicine Inc., a clinical-stage biotech company, has announced its intention to apply to the Canadian Securities Regulators for an order to cease being a reporting issuer in British Columbia, Ontario, and Alberta. If granted, Clearmind will no longer be required to file financial statements and other continuous disclosure documents with the Canadian Securities Regulators. However, the company will continue to file all necessary financial statements and other continuous disclosure materials in accordance with the laws of the United States and Germany, and the rules of The Nasdaq Capital Market and the Frankfurt Stock Exchange.

Growth-Positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This partnership will focus on the development of generation 3.0 psychedelic compounds for the treatment of addiction and mental disorders. The agreement grants Clearmind exclusive worldwide rights to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds. This move is expected to strengthen Clearminds position in the market and expand its innovative portfolio in addiction and mental health treatments.

Growth-Positive

Clearmind Medicine Inc., a clinical-stage biotech company, has filed a patent application with the United States Patent and Trademark Office for the use of 3-methylmethcathinone (3-MMC) to prevent and/or treat eating disorders. The company believes that its molecules may have the potential over the ones already available in the market. Clearmind is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. The companys shares are listed for trading on Nasdaq and the Frankfurt Stock Exchange.

Growth-Positive

Clearmind Medicine Inc., a clinical-stage biotech company, has made significant advances in 2023, particularly with its flagship compound, CMND-100, which is aimed at treating alcohol use disorder and other addictive disorders. The company has recently received approval from the Israeli Ministry of Health for its Phase I/IIa clinical trial for CMND-100. The company has also formed key partnerships for manufacturing and contract research organization support and has secured IRB Approval for its clinical trial in Israel. Clearmind has also announced Johns Hopkins University and Yale School of Medicine’s Department of Psychiatry as the first U.S. sites for its clinical trial.

growth-positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has submitted its tenth patent application in collaboration with SciSparc Ltd. The patent pertains to Clearminds MEAI compound and its potential use in treating depression. This application follows nine other patent applications filed by Clearmind for various compositions, including the treatment of alcohol use disorder, cocaine addiction, and obesity. The global depression and anxiety disorders treatment market is projected to reach USD 41.83 billion by 2034. Clearmind aims to develop novel psychedelic drugs to address unmet mental health needs.

growth-positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has been granted a divisional patent approval by the China National Intellectual Property Administration. This patent grants Clearmind a broader claim than the patent application and covers primary amine aminoindan compounds, including the companys innovative psychedelic molecule, MEAI. The companys MEAI-based treatment focuses on Alcohol Use Disorder and binge drinking. The approval of this patent significantly expands Clearminds IP protection in the psychedelic space.

growth-positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, has announced its voluntary delisting from the Canadian Securities Exchange (CSE). The company believes that the trading volume of its shares on the CSE no longer justifies the expenses and administrative efforts required to maintain a dual listing. Clearmind will continue to trade on the NASDAQ under the symbol CMND. The company expects this move to create a central marketplace for its shares on the NASDAQ, benefiting long-term liquidity and shareholder value.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the companys proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule. The trial will be conducted in Israel and two additional sites in the United States. The primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics of single and repeated doses of CMND-100 in healthy subjects and those with AUD. The secondary endpoint is to evaluate the preliminary efficacy of CMND-100 in reduction of drinking patterns and cravings in individuals with moderate-to-severe AUD.

Growth-Positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, has submitted three additional patent applications as part of its ongoing collaboration with SciSparc Ltd. The patent applications refer to novel proprietary compositions of MDMA, Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide™. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (USPTO). The company now has 27 granted patents and 24 pending patent applications across 15 patent families.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced its ongoing collaboration with Clearmind Medicine Inc., a biotechnology company. As part of this collaboration, Clearmind filed three patent applications for novel proprietary compositions of MDMA, ibogaine, and ketamine, each combined with the active ingredient of SciSparcs proprietary CannAmide. These applications were previously filed as provisional patent applications with the USPTO. Additionally, eight other applications have been filed by Clearmind with the USPTO for various combinations.

growth-positive

Clearmind Medicine Inc has announced the granting of divisional patent approval by the China National Intellectual Property Administration (CNIPA). This strengthens the companys patent protection for its flagship molecule and expands its intellectual property protection in the psychedelic space. The companys IP portfolio now includes fifteen utility patent families, with 24 pending patent applications and 27 granted patents in key jurisdictions. The companys flagship molecule, MEAI, has shown promise in reducing the desire to consume alcoholic beverages. Clearmind plans to commence clinical trials for alcohol use disorder, expand their IP portfolio, and explore MEAIs potential in treating obesity.

growth-positive

Clearmind Medicine Inc. has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the companys proprietary MEAI-based CMND-100 oral capsule. The trial will be led by Prof. Mark Weiser, M.D., at the Sheba Medical Center in Ramat Gan, with additional sites in the United States at the Yale School of Medicine’s Department of Psychiatry and the Johns Hopkins University School of Medicine. The primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics of single and repeated doses of CMND-100 in healthy subjects and those with AUD.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced an ongoing collaboration with Clearmind Medicine Inc., a biotechnology company. As part of this collaboration, Clearmind has filed three patent applications for novel proprietary combinations of various compounds, including the active ingredient of SciSparcs proprietary CannAmide™. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office. SciSparcs CEO, Oz Adler, expressed his pleasure at the continued collaboration and the expansion of the intellectual property portfolio.

Growth-Positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has submitted three patent applications under the international Patent Cooperation Treaty (PCT). This is part of its ongoing collaboration with SciSparc Ltd., a pharmaceutical company focusing on therapies for central nervous system disorders. The patents refer to novel combinations of LSD, psilocybin, DMT, and SciSparcs Palmitoylethanolamide (PEA). Clearminds IP portfolio now includes 27 granted patents and 24 pending applications across 15 patent families. The company aims to commercialize psychedelic-based compounds as regulated medicines, foods, or supplements.

growth-negative

The article discusses the recent developments in the cannabis and psychedelic sectors. Canopy Growth Corporation reported a CA$216.7 million loss and a 7% decrease in total net revenue, primarily due to lower Canadian cannabis sales. Aurora Cannabis Inc. acquired the remaining 90% equity interest of MedReleaf Australia, expanding its presence in the Australian medical cannabis market. Ayr Wellness Inc. extended the maturity date of senior notes from 2024 to 2026 and raised $40 million in new capital. Curaleaf International acquired Can4Med, marking its entry into the Polish medical cannabis market. In the psychedelic sector, Awakn Life Sciences Corp.s Phase III clinical trial for AWKN-001 was recognized in Psyched Alpha’s psychedelic drug development pipeline bullseye chart. Clearmind Medicine Inc. secured patent approval in China for a novel psychedelic substance-based treatment targeting binge behaviors.

Growth-Positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, has been granted a divisional patent approval by the China National Intellectual Property Administration. This patent establishes the companys protection around its flagship molecule and its extensive IP protection in the psychedelic space. Clearmind’s IP portfolio consists of 15 utility patent families, including patents and applications having method of use and composition of matter claims. The companys MEAI-based flagship treatment focuses on Alcohol Use Disorder. Clearmind intends to seek additional patents for its compounds and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

growth-positive

Clearmind Medicine Inc., a biotech company focused on developing psychedelic-derived therapeutics, has signed an exclusive long-term license agreement with BIRAD, a research & development company of Bar-Ilan University. The agreement pertains to the joint patent for an innovative cocaine treatment. Clearmind has reported positive pre-clinical results for the treatment of cocaine addiction using its novel psychedelic molecule, MEAI. The company aims to secure the long-term, exclusive rights to the technology to ensure maximum returns for shareholders and to provide innovative treatments for addiction using psychedelic compounds.

growth-positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, has closed its previously announced definitive agreements with institutional investors. The agreements involve the purchase and sale of Common Shares and Pre-Funded Warrants in a registered direct offering. Concurrently, the company also agreed to sell Common Warrants to the same investors in a private placement. The total gross proceeds from both transactions were approximately $2.4 million. The company plans to use the net proceeds for general corporate purposes and working capital.

growth-positive

Aegis Capital Corp. has acted as the sole bookrunner on a $2.4 million registered direct and private placement for Clearmind Medicine Inc., a pre-clinical pharmaceutical company that develops novel psychedelic medicines to treat under-served health problems. Clearmind Medicine Inc. is also collaborating with Aegis Capital Corp. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome.

growth-positive

Clearmind Medicine Inc., a biotech company developing psychedelic-derived therapeutics, has entered into definitive agreements with institutional investors for the purchase and sale of Common Shares and pre-funded warrants in a registered direct offering. The company also agreed to sell Common Warrants to the same investors in a concurrent private placement. The transactions are expected to generate approximately $2.4 million in gross proceeds. The funds will be used for general corporate purposes and working capital. The transactions are expected to close on January 16, 2024.

Growth-Positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss its clinical trial of CMND-100, a proprietary MEAI-based compound for the treatment of Alcohol Use Disorder (AUD). The active ingredient in CMND-100, MEAI, has been reported to reduce the desire to consume alcoholic beverages while providing a euphoric alcohol-like experience. Clearmind aims to commercialize psychedelic-based compounds as regulated medicines, foods, or supplements, and currently has fifteen patent families in its intellectual portfolio.

growth-positive

Clearmind Medicine Inc. reflects on its successful collaboration with SciSparc Ltd. in 2023, which involved filing six US patent applications for unique combinations of future psychedelic-based compounds. These applications were part of Clearminds ongoing collaboration with SciSparc, a specialty clinical-stage pharmaceutical company. The patent applications are part of Clearminds commitment to offer patients safer and more effective treatments than those available today by strengthening its IP portfolio. Clearmind has a broad IP footprint in the psychedelic space, with 51 patents in 15 utility patent families. Any assets generated from the collaboration will be jointly owned by Clearmind and SciSparc.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, reflects on its successful collaboration with Clearmind Medicine Inc. in 2023. The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of psychedelics with SciSparcs proprietary CannAmide. The patent applications represent a commitment by SciSparc and Clearmind to offer patients safer and more effective treatments than those available today partly by strengthening their IP portfolios to broaden the therapeutic psychedelic toolbox for patients with mental health disorders.

Growth-Positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, has regained compliance with the minimum bid price requirement set by Nasdaq. The companys common shares maintained a minimum bid price of $1.00 per share for 10 consecutive business days, leading to the cancellation of a scheduled hearing before the Nasdaq Listing Qualifications Hearings Panel. Clearminds shares will continue to be listed and traded on Nasdaq.

growth-positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced positive results in its treatment for cocaine addiction. The treatment is based on the companys innovative psychedelic molecule, MEAI. The trials were led by Professor Gal Yadid and his team from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel. The companys research has resulted in a patent application in the U.S. and is part of an ongoing collaboration with SciSparc Ltd., a specialty clinical-stage pharmaceutical company. The collaboration involves combining Clearminds MEAI with SciSparcs CannAmide™.

growth-positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, announced positive results from its pre-clinical trial for obesity and metabolic disorders. The trial, led by Professor Joseph Tam from The Hebrew University of Jerusalem, used a combination of Clearminds MEAI and SciSparcs Palmitoylethanolamide (PEA). The treatment showed a remarkable degree of tolerance, increased metabolic processes and fat oxidation, and reduced appetite. Clearminds CEO, Dr. Adi Zuloff-Shani, expressed confidence in the MEAI-based treatment and its potential as a safer option for weight-loss drugs.

growth-positive

Clearmind Medicine Inc., a biotech company focused on developing novel psychedelic-derived therapeutics, has announced positive results from its pre-clinical trial. The trial, led by Professor Joseph Tam from The Hebrew University of Jerusalem, tested a treatment combining Clearminds MEAI and SciSparcs Palmitoylethanolamide (PEA) for various addictions, obesity, and metabolic disorders. The treatment showed potential effects in various metabolic parameters including fat oxidation, weight loss, and reduced appetite. Clearminds CEO, Dr. Adi Zuloff-Shani, believes their proprietary drug candidate, MEAI, is a potentially better and safer option compared to other weight-loss drugs currently on the market.

growth-positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, will participate in a virtual event discussing the current psychedelic renaissance. The event, part of The Psychedelic Association of Canadas Industry Presents Series, will feature Clearminds CEO, Dr. Adi Zuloff-Shani, and MAPS founder, Rick Doblin. They will discuss the benefits of traditional and novel psychedelics, as well as the companys innovative MEAI molecule. The event will be held on November 29, 2023.

Growth-Negative

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced a reverse share split of its issued and outstanding ordinary shares at a ratio of 1-for-30. This move is part of the companys plan to regain compliance with the Nasdaq Minimum Bid Price Rule. The reverse split, approved by shareholders and the companys board of directors, will reduce the number of issued and outstanding Common Shares from 18,221,419 to 607,381. The companys authorized share capital will remain unchanged.

growth-negative

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has received a Staff Delisting Determination from the Nasdaq Stock Market due to failure to maintain a minimum bid price of $1.00 per share for thirty consecutive business days. The company plans to appeal this decision and as part of their plan to regain compliance, they intend to conduct a reverse stock split, which has already been approved by shareholders. The companys CEO, Dr. Adi Zuloff-Shani, has expressed optimism about regaining compliance with the Minimum Bid Price Rule.

growth-positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced that all matters proposed at its recent shareholder meeting were approved. This includes the decision to fix the board of directors at four members, the election of directors for the coming year, the establishment of an omnibus equity incentive plan, and the approval for the directors to consolidate the companys common shares. The company, which is listed on Nasdaq and the Canadian Securities Exchange, is focused on solving widespread health problems, including alcohol use disorder.

growth-positive

Clearmind Medicine Inc. has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The trial will be a multinational, multi-center study in healthy volunteers and AUD subjects. The primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics of single and repeated doses of CMND-100 in healthy subjects and those with AUD.

Growth-Positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, announced that its CEO, Dr. Adi Zuloff-Shani, will be participating in the 8th Annual Dawson James Conference on October 12, 2023. The company aims to solve major under-treated health problems and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements. Clearminds intellectual portfolio consists of fifteen patent families and the company plans to seek additional patents for its compounds.

growth-positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced that its CEO, Dr. Adi Zuloff-Shani, will be participating in the LD Micro Main Event XVI Conference in Los Angeles, California. The conference is scheduled to take place from October 3-5, 2023. Clearmind is focused on solving widespread and underserved health problems, including alcohol use disorder, through the discovery and development of novel psychedelic-derived therapeutics. The company currently has fifteen patent families and plans to seek additional patents for its compounds.

growth-positive

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, has raised $2.25 million in a public offering with Aegis Capital Corp. acting as the exclusive placement agent. The company, which develops novel psychedelic medicines to treat under-served health problems, is collaborating with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021.

Growth-Positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, has closed a US-only public offering, raising approximately US$2.25 million. The offering consisted of 7.5 million common shares and pre-funded warrants. The proceeds will be used for general corporate purposes, including operating expenses, R&D, working capital, future acquisitions, and capital expenditures. The offering was not made in Canada and no securities were purchased by Canadian residents. Aegis Capital Corp. acted as the exclusive placement agent for the offering.

Growth-Positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced the pricing of its US-only public offering, expecting to raise approximately $2.25 million before fees and expenses. The offering, which consists of 7.5 million common shares and pre-funded warrants, is expected to close on September 18, 2023. The proceeds will be used for general corporate purposes, including R&D, working capital, future acquisitions, and capital expenditures. The offering is not available to Canadian residents. Aegis Capital Corp. is the exclusive placement agent for the offering.

growth-positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced a Clinical Trial Agreement with Johns Hopkins University School of Medicine (JHU) to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100. This trial aims to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and those with Alcohol Use Disorder (AUD). The secondary end point is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and cravings, in individuals with moderate-to-severe AUD.

growth-positive

Clearmind Medicine Inc. has announced a collaboration with CTS Ltd. for product development. CTS is a leading pharmaceutical and consumer products company in Israel. The collaboration will provide Clearmind Medicine with access to CTS facilities, networks, and industry connections, as well as expertise in manufacturing and marketing. Clearmind Medicine aims to revolutionize mental health treatments through the development of psychedelic-based therapeutics. The collaboration signifies the growing interest in this field within the pharmaceutical industry.

growth-positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has filed a provisional patent application with the US Patent and Trademark Office for the treatment of Dyskinesia. The patent application refers to the psychedelic molecule 3-Methylmethcathinone (3-MMC) as a potential treatment for Dyskinesia, thus expanding Clearmind’s IP portfolio. The patent application also includes protection for its unique combination of 3-MMC and SciSparcs Palmitoylethanolamide for the treatment of Dyskinesia, as part of its ongoing collaboration with SciSparc Ltd.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has filed a new U.S. patent application in collaboration with Clearmind Medicine Inc. The patent is for the use of the psychedelic molecule 3-MMC and SciSparcs Palmitoylethanolamide to treat dyskinesia and dystonia, which are known to occur in several rapid, non-rhythmic, abnormal movements disorders including Tourette Syndrome and Parkinsons disease. The patent application was filed with the United States Patent and Trademark Office.

Growth-Positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, has issued 17,899 common shares in lieu of the final payment of $10,000 to consultants of the company. Additionally, the company has issued restricted stock units for another consultant in lieu of a $5,000 payment. The company is primarily focused on researching and developing psychedelic-based compounds to address widespread and underserved health problems, including alcohol use disorder.

growth-positive

Clearmind Medicine Inc., a biotech company developing psychedelic-derived therapeutics, has appointed Dr. Fatima Cody Stanford to its Scientific Advisory Board. Dr. Stanford, an Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School, brings extensive expertise in obesity treatment. This aligns with Clearminds mission to transform obesity treatment by advancing MEAI as a potential solution. A pre-clinical study conducted at the Hebrew University of Jerusalem showed that obese animals treated with MEAI exhibited increased energy expenditure, better fat utilization, and weight loss of 20%, among other benefits.

growth-positive

Clearmind Medicine Inc. has entered into a research agreement with the Hebrew University of Jerusalem to evaluate its combination treatment for obesity and metabolic syndrome. The treatment combines Clearminds MEAI, a psychedelic treatment for addictions, and SciSparcs Palmitoylethanolamide (PEA). The study will be led by Professor Joseph Tam and will evaluate the effect of the combination on food intake, metabolic profiles, and activity. Previous pre-clinical studies have shown positive results in treating obesity with MEAI. Clearminds collaboration with SciSparc has resulted in patent applications for combination therapies for various disorders. Clearmind is a biotech company focused on the development of psychedelic-derived therapeutics, while SciSparc is a pharmaceutical company focusing on therapies for the central nervous system.

growth-positive

SciSparc Ltd has announced a research agreement with Clearmind Medicine Inc. and the Hebrew University of Jerusalem to evaluate a proprietary combination treatment for obesity and metabolic syndrome. The treatment combines SciSparcs Palmitoylethanolamide (PEA) and Clearminds Methoxy-2-aminoindane (MEAI). The collaboration aims to develop ground-breaking treatments for global health challenges. Previous pre-clinical studies have shown promising results, including weight loss, improved fat utilization, and normalization of insulin levels. The treatment also demonstrated the potential to reduce compulsive reward-seeking behavior. SciSparc is a specialty clinical-stage pharmaceutical company focused on developing therapies for disorders of the central nervous system. Clearmind Medicine is a biotech company focused on psychedelic-derived therapeutics. The research agreement signifies SciSparcs commitment to delivering innovative treatments.

growth-positive

Clearmind Medicine Inc., a biotech company developing psychedelic-derived therapeutics, will host a virtual investor conference on June 12, 2023, titled Psychedelics for Obesity. The conference will discuss the companys recent positive pre-clinical results demonstrating the efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome. The study was led by Professor Joseph Tam from the Hebrew University’s Institute for Drug Research. Clearminds CEO, Dr. Adi Zuloff-Shani, will present the companys achievements and goals during the conference.

growth-positive

Clearmind Medicine Inc. has selected Yale School of Medicine as its first U.S. site for the companys Phase I/IIa clinical trial of its CMND-100 compound for the treatment of alcohol use disorder. The trial will be led by Dr. Anahita Bassir Nia, a specialist in substance abuse. Clearmind believes that CMND-100 has the potential to be a game-changer in treating addictions and mental health concerns. The company aims to develop psychedelic-derived therapeutics to solve underserved health problems. Clearminds intellectual property portfolio consists of fourteen patent families. Shares of Clearmind are listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange.

growth-negative

Clearmind Medicine Inc. has received a notice from Nasdaq indicating that it is not in compliance with the minimum bid price requirement for continued listing. The company has been granted a grace period of 180 calendar days to regain compliance. If the company does not regain compliance within the given period, its ordinary shares may be subject to delisting. Clearmind Medicine is a biotech company focused on the discovery and development of psychedelic-derived therapeutics.

growth-positive

Clearmind Medicine Inc. has received Ethics Committee approval for its CM-CMND-001 Phase I/II clinical trial of its CMND-100 compound for the treatment of alcohol use disorder (AUD) at Israel’s IMCA center. The primary end point of the trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of CMND-100. The secondary end point is to evaluate the efficacy of CMND-100 in reducing drinking patterns and craving in individuals with AUD. Clearmind aims to revolutionize AUD treatment with CMND-100, which has shown significant and immediate reduction of alcohol cravings and consumption in pre-clinical studies. The company believes CMND-001 holds tremendous potential as an alternative to current approaches.

growth-positive

Clearmind Medicine Inc. has retained Crescendo Communications for strategic investor relations and capital markets communications services. The company has also issued shares and warrants to consultants and providers of investor services. Clearmind Medicine is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics. It aims to solve under-treated health problems, including alcohol use disorder. The company holds fourteen patent families and intends to seek additional patents and acquire intellectual property. Clearmind Medicine is listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange.

growth-positive

Clearmind Medicine Inc. has appointed Professor Joseph Tam to its Scientific Advisory Board. Prof. Tam is an expert on obesity and metabolic syndrome and is the Head of the Obesity and Metabolism Laboratory at the Hebrew University of Jerusalem. Clearmind aims to work with leading researchers to develop psychedelic-derived therapeutics for addictions and mental health disorders. The company believes that Prof. Tams research could make a significant difference in treating obesity and metabolic disorders. Clearmind is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics. It has a strong IP portfolio and is listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange.

growth-positive

Clearmind Medicine Inc. has announced an agreement with IMP Clinical Supply Services for the global clinical supply chain of its drug candidate CMND-100. The collaboration aims to ensure the success of Clearminds clinical trial, which is expected to begin in Q2 2023. The trial will focus on finding the tolerable dose and evaluating the safety, pharmacokinetics, and pharmacodynamics of CMND-100 in healthy subjects and those with Alcohol Use Disorder (AUD). The secondary endpoint is to assess the efficacy of CMND-100 in reducing drinking patterns and craving in individuals with moderate-to-severe AUD. The market size for AUD treatment is projected to increase by 8.8% until 2032. Clearmind is a biotech company focused on developing psychedelic-derived therapeutics.

growth-positive

Clearmind Medicine Inc. has formed a Data and Safety Monitoring Board (DSMB) to oversee the companys first clinical trial for Alcohol Use Disorder (AUD) treatment. The DSMB is responsible for reviewing clinical trial data to ensure the safety of study subjects and the integrity of the data. Clearmind Medicine is a biotech company focused on the discovery and development of psychedelic-derived therapeutics to address under-treated health problems. The company aims to research and develop psychedelic-based compounds and commercialize them as regulated medicines, foods, or supplements. Clearminds intellectual portfolio consists of fourteen patent families, and the company is open to acquiring additional intellectual property.

growth-positive

SciSparc Ltd, a specialty clinical-stage pharmaceutical company, announced a collaboration with Clearmind Medicine Inc. to develop novel psychedelic-derived therapies for mental health disorders. Clearmind filed a provisional patent application with the USPTO to protect the combination of SciSparcs Palmitoylethanolamide (PEA) and MEAI for the treatment of depression. Several other patent applications have been filed for the combination of PEA with different compounds for the treatment of alcohol use disorder, cocaine addiction, obesity, and metabolic disorders. SciSparc is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals, with ongoing drug development programs for various conditions. The company also owns a subsidiary that sells hemp-based products on Amazon.com.

growth-positive

Clearmind Medicine Inc. has filed a patent application to protect its unique combination of MEAI and SciSparcs Palmitoylethanolamide (PEA) for the treatment of depression. The patent application is part of Clearminds collaboration with SciSparc Ltd., a pharmaceutical company focused on therapies for central nervous system disorders. This patent adds to Clearminds existing intellectual property portfolio in the psychedelic space. The company has a total of 24 patents in 14 patent families, with nine already granted in major jurisdictions. Clearmind aims to broaden the therapeutic options for patients with mental health disorders while reducing costs. The companys primary objective is to develop psychedelic-derived therapeutics and commercialize them as regulated medicines, foods, or supplements.

growth-positive

Clearmind Medicine Inc. has announced preparations for its first-in-human clinical trial of the drug candidate CMND-100 for the treatment of Alcohol Use Disorder. The company has engaged a contract research organization (CRO) to provide support for the trial. The CRO will act as a project manager and provide various forms of support throughout the trial. Clearmind Medicine is a biotech company focused on the discovery and development of psychedelic-derived therapeutics to address under-treated health problems. The company aims to commercialize its compounds as regulated medicines, foods, or supplements. Clearminds shares are listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange.

growth-positive

Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Public Offering for Clearmind Medicine Inc., a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics. Clearmind aims to commercialize these compounds as regulated medicines, foods, or supplements. They currently hold 13 patent families and plan to seek additional patents and acquire intellectual property. Aegis Capital Corporation, a wealth management and investment banking firm, provided corporate finance and advisory services for the offering.

growth-positive

Clearmind Medicine Inc. has announced the closing of its public offering in the United States, raising approximately US$3.5 million in gross proceeds. The offering consisted of common shares and warrants. The company plans to use the net proceeds for general corporate purposes, including research and development, future acquisitions, and general capital expenditures. The offering was made through Aegis Capital Corp. as the exclusive placement agent. Clearmind Medicine is a biotech company focused on the discovery and development of psychedelic-derived therapeutics. The companys intellectual portfolio currently consists of 13 patent families.

growth-positive

Clearmind Medicine Inc. has announced the closing of its public offering, raising approximately US$3.5 million in gross proceeds. The offering consisted of common shares and warrants, with the net proceeds expected to be used for general corporate purposes, research and development, future acquisitions, and capital expenditures. The offering was made exclusively in the United States and was facilitated by Aegis Capital Corp. Clearmind is a biotech company focused on the discovery and development of psychedelic-derived therapeutics. The company aims to solve under-treated health problems and has a portfolio of 13 patent families. Its shares are listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange.

growth-positive

Clearmind Medicine Inc. has announced the pricing of its public offering, with gross proceeds expected to be approximately US$3.5 million. The offering consists of common shares and warrants. The company plans to use the net proceeds for general corporate purposes, including research and development, future acquisitions, and general capital expenditures. The offering is expected to close on April 6, 2023. Clearmind Medicine is a biotech company focused on the discovery and development of psychedelic-derived therapeutics. It is listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange.

growth-positive

Clearmind Medicine Inc. has submitted an IND application with the FDA to initiate a Phase I/IIa clinical trial for CMND-100, a psychedelic-derived therapeutic for alcohol use disorder. The company plans to start the trial in Q2 2023. CMND-100 contains MEAI, a psychoactive molecule that has shown potential to reduce the desire to consume alcohol. Alcohol use disorder affects millions of people globally and causes significant healthcare costs. The market for AUD treatment is expected to grow by 8.8% by 2032. Clearmind is focused on developing psychedelic-based compounds to address underserved health problems.

growth-positive

Clearmind Medicine Inc. has announced the appointment of Professor Henry R. Kranzler to its Scientific Advisory Board. Professor Kranzler is an expert in addiction medicine and will contribute his knowledge and expertise to Clearminds work in developing psychedelic-derived therapeutics for alcohol and substance use disorders. Clearmind is a biotech company focused on the discovery and development of novel psychedelic-based compounds. The companys intellectual portfolio consists of 13 patent families, and it intends to seek additional patents and acquire additional intellectual property. Clearminds shares are listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange.

growth-positive

SciSparc Ltd announced that Clearmind Medicine Inc. has filed three provisional patent applications for unique combinations of future psychedelic-based compounds as part of their ongoing collaboration. Clearmind has also filed other patent applications for various combinations, including the combination of SciSparcs PEA with Clearminds MEAI compound for the treatment of alcohol use disorder, cocaine addiction, obesity, and related metabolic disorders. The collaboration agreement states that any assets generated from the collaboration will belong to both companies. SciSparc is a specialty clinical-stage pharmaceutical company focused on the development of therapies for disorders of the central nervous system, while Clearmind is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics. The article does not mention any specific customers, acquisition or investment amounts, layoffs, or partners involved.

growth-positive

Clearmind Medicine Inc. has filed three provisional patent applications with the United States Patent and Trademark Office for unique combinations of psychedelic-based compounds in collaboration with SciSparc Ltd. The patent applications aim to broaden the therapeutic psychedelic toolbox for patients with mental health disorders. Clearmind has a strong intellectual property portfolio in the psychedelic space, with 29 patents in 13 patent families. The company plans to continue being pioneers in the field of novel psychedelic compounds and treatments.